Cytosorbents files appeal with u.s. fda for supervisory review of its de novo request for drugsorb™-atr

Princeton, n.j. , june 24, 2025 /prnewswire/ -- cytosorbents corporation (nasdaq: ctso), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on june 18, 2025, it filed a request for supervisory review (administrative appeal) with the u.s. food and drug administration (fda) under 21 cfr 10.75, of the de novo denial letter issued on april 25, 2025 for cytosorbents' drugsorb-atr device,  (the denial letter).
ATR Ratings Summary
ATR Quant Ranking